These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10160053)

  • 21. Relationship of stage mensuration data to the performance of new and used cascade impactors.
    Roberts DL; Romay FJ
    J Aerosol Med; 2005; 18(4):396-413. PubMed ID: 16379616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardization issues: in vitro assessment of nebulizer performance.
    Dennis JH
    Respir Care; 2002 Dec; 47(12):1445-55; discussion 1455-8. PubMed ID: 12467502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhalation devices--which is best for your patient?
    Yule H
    Hosp Pharm; 1992 Nov; 27(11):1010-2, 1015. PubMed ID: 10122038
    [No Abstract]   [Full Text] [Related]  

  • 24. Entry port selection for detecting particle size differences in metered dose inhaler formulations using cascade impaction.
    Naini V; Chaudhry S; Berry J; Sharpe S; Hart J; Sequeira J
    Drug Dev Ind Pharm; 2004 Jan; 30(1):75-82. PubMed ID: 15000432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical nebulizer performance: effects of cascade impactor temperature.
    Zhou Y; Ahuja A; Irvin CM; Kracko DA; McDonald JD; Cheng YS
    Respir Care; 2005 Aug; 50(8):1077-82. PubMed ID: 16225713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung deposition and respirable mass during wet nebulization.
    Sangwan S; Condos R; Smaldone GC
    J Aerosol Med; 2003; 16(4):379-86. PubMed ID: 14977428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor.
    Kwong WT; Ho SL; Coates AL
    J Aerosol Med; 2000; 13(4):303-14. PubMed ID: 11262437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree.
    Christopher D; Curry P; Doub B; Furnkranz K; Lavery M; Lin K; Lyapustina S; Mitchell J; Rogers B; Strickland H; Tougas T; Tsong Y; Wyka B;
    J Aerosol Med; 2003; 16(3):235-47. PubMed ID: 14572321
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of tubing deposition, breathing pattern, and temperature on aerosol mass distribution measured by cascade impactor.
    Gurses BK; Smaldone GC
    J Aerosol Med; 2003; 16(4):387-94. PubMed ID: 14977429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of preseparator performance for the 8-stage nonviable andersen impactor.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2001 Mar; 2(1):E4. PubMed ID: 14727889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design.
    Marple VA; Roberts DL; Romay FJ; Miller NC; Truman KG; Van Oort M; Olsson B; Holroyd MJ; Mitchell JP; Hochrainer D
    J Aerosol Med; 2003; 16(3):283-99. PubMed ID: 14572326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AARC (American Association for Respiratory Care) clinical practice guideline. Delivery of aerosols to the upper airway.
    Respir Care; 1994 Aug; 39(8):803-7. PubMed ID: 10146087
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimizing nebulization practice.
    Kendrick AH; Smith EC
    Respir Med; 1996 May; 90(5):315. PubMed ID: 9499817
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimizing nebulization practice.
    Burnett H
    Respir Med; 1996 May; 90(5):315-6. PubMed ID: 9499818
    [No Abstract]   [Full Text] [Related]  

  • 36. Aerosol consensus statement--1991. American Association for Respiratory Care.
    Respir Care; 1991 Sep; 36(9):916-21. PubMed ID: 10145538
    [No Abstract]   [Full Text] [Related]  

  • 37. Aerosol generators and delivery systems.
    Newman SP
    Respir Care; 1991 Sep; 36(9):939-51. PubMed ID: 10145539
    [No Abstract]   [Full Text] [Related]  

  • 38. AARC clinical practice guideline. Selection of aerosol delivery device. American Association for Respiratory Care.
    Respir Care; 1992 Aug; 37(8):891-7. PubMed ID: 10145780
    [No Abstract]   [Full Text] [Related]  

  • 39. United States Pharmacopeia recommendations for the testing of inhalers.
    Byron PR
    J Aerosol Med; 1998; 11 Suppl 1():S11-12. PubMed ID: 10180721
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing parallelism prior to determining relative potency.
    Hauck WW; Capen RC; Callahan JD; De Muth JE; Hsu H; Lansky D; Sajjadi NC; Seaver SS; Singer RR; Weisman D
    PDA J Pharm Sci Technol; 2005; 59(2):127-37. PubMed ID: 15971545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.